Top COVID-19 vaccination challenges
By James D. Dawes, MHA, COE, CMPE
The U.S. Food and Drug Administration has given emergency use authorization for two COVID-19 vaccines, with another one expected to be approved soon. Along with the hope it brings, vaccination has brought several challenges that I’ve heard in my regular conversations with frontline managers in ophthalmic practices and ASCs. Below, I list three of the most common challenges and, where appropriate, suggestions for how to address them.
- Challenge #1 - Getting the vaccine. Since vaccine distribution began in the United States on Dec. 14, more than 42 million doses have been administered, reaching 9.7% of the total U.S. population, according to federal data collected by the Centers for Disease Control and Prevention at press time. The United States is administering around 1.4 million shots a day. With the elderly and direct line healthcare workers at the front of the line, it will take months for enough people to get vaccinated to end the pandemic, according to estimates. For information about getting the vaccine, visit bit.ly/OPCDCvaccines .
- Challenge #2 – Fitting a vaccination appointment into the clinic schedule. Many healthcare workers are being notified of an appointment or opportunity to get the vaccine. However, that appointment often falls during their normal patient hours. Unfortunately, many are concerned that if they do not accept the appointment, they will fall to the back of the line. Leaving the office in the middle of the day for a vaccination can be a challenge for many front-line workers. Practices can help address this challenge by scrutinizing coordination of patient care, staff schedules, and protocols to ensure the safety of our teams and patients.
- Challenge #3 – Becoming a vaccination site. Some ophthalmic practices have expressed a desire to serve as a vaccination site, particularly given the age and risk of our patient population. The application and approval process to become a provider of vaccines can be arduous. Several large ophthalmic practices have made the decision to administer the vaccine, and many have been approved. Unfortunately, in most states there is simply not enough vaccine to be distributed to all the potential vaccination sites, with some states recently reporting backlogs and/or canceled appointments due to limited supplies. As the FDA approves additional vaccines, this situation will improve. However, significant details need to be coordinated at the federal, state, and local levels to coordinate the logistics of distribution. For vaccination program provider requirements visit bit.ly/OPCDCProvider .
Keep in mind the vaccine is not a silver bullet, as healthcare professionals must continue to follow CDC guidelines for social distancing, mask wearing, safety, and sanitization protocols in our office while we pursue vaccines for ourselves, our families, and our patients. If you are struggling with the on-going safety protocols, COVID fatigue, and, more recently, vaccination issues, then know you are not alone. But things will get better. As we move into 2021 and the months to come, we must continue to be diligent in our responsibilities. Onward. OP
In Brief
The American Society of Cataract and Refractive Surgery (ASCRS) annual meeting was rescheduled to July 23 to 27 in Las Vegas, Nev., at the Mandalay Bay Convention Center. The meeting was originally scheduled to take place in San Francisco, Calif., but “due to the current restrictions” in that city the ASCRS was unable to hold the meeting there, according to an official ASCRS statement. Registration opened on Feb. 22, with housing information soon to follow.
Johnson & Johnson Vision received FDA approval for the TECNIS Eyhance and TECNIS Eyhance Toric II IOLs for the treatment of cataract patients. These newest monofocal lenses in the TECNIS line feature extended depths of focus, better image contrast in low light and compatibility with the new TECNIS Simplicity system, which streamlines lens delivery and protects against contamination.
Modernizing Medicine’s EMA EHR system is now updated for the E/M coding changes that took effect at the start of this year. The system’s suggested coding capabilities will now reflect the new guidelines. For example, as of Jan. 1, 2021, a clinician can choose to bill based on total time or medical decision-making (MDM). If they choose MDM, the platform will be able to automatically suggest the relevant E/M code based on the user’s clinical documentation and related MDM.
Genentech announced positive topline results from the Phase 3 global TENAYA and LUCERNE studies evaluating faricimab in people living with neovascular or “wet” age-related macular degeneration (nAMD). Faricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways — via angiopoietin-2 and vascular endothelial growth factor-A — that drive a number of retinal conditions, including nAMD.
Omeros announced that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The separate payment falls under CMS’ policy for non-opioid pain management surgical drugs when used in the ASC setting.